ArticleChemical science2025
Donor modulation brings all-in-one phototheranostics for NIR-II imaging-guided type-I photodynamic/photothermal synergistic cancer therapy.
Article in Chemical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Controlled In Situ Self-Assembly for Pretargeted Tumor Theranostics via Bioorthogonal Activation.Advanced healthcare materials · 2026Article
- Illuminating the path to oncolysis: rise of microbial phototherapy.Journal of nanobiotechnology · 2026Review
- Fluorinated Hypoxia-Responsive Aza-BODIPY for NIR-II FL/Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Design of benzo[1,2-b:4,3-b']dithiophene-4,5-dione based donor-acceptor-donor small molecules for efficient near-infrared photothermal therapy.Communications chemistry · 2026Article
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- AI-engineered multifunctional nanoplatforms: synergistically bridging precision diagnosis and intelligent therapy in next-generation oncology.Journal of nanobiotechnology · 2025Review
- Engineering Separated Dual OAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nitric oxide-activatable NIR-II organic small molecule for fluorescence imaging-guided synergistic photodynamic and photothermal therapy.Chemical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type-I photodynamic (PDT) and photothermal (PTT) synergistic therapy guided by fluorescence imaging in the near-infrared region II (NIR-II) is crucial for cancer diagnosis and treatment. Phototheranostics provide a promising system for efficient imaging-guided phototherapy, combining diagnostics with therapeutics within a single photosensitizer and avoiding the complexity of composition and low reproducibility of combination methods. Herein, we design and synthesize an all-in-one phototheranostic agent OTAB by modifying aza-BODIPY with a methoxy group substituted triphenylamine moiety, followed by the formation of nanoparticle OTAB@cRGD NPs
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.